Jorge Romaguera, MD | Authors

KROGER CORP

6322 TELEPHONE RD

Articles

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphomas

August 01, 2002

Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin’s lymphomas (NHLs). Irinotecan at 300 mg/m² IV was administered every 21 days with intensive loperamide management of diarrhea.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphoma

July 01, 2001

Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity. Various schedules and doses have been studied, and major complications were delayed diarrhea and